Last reviewed · How we verify

Intra-articular corticosteroid injections (intra-articular-corticosteroid-injections)

Pfizer · FDA-approved active Quality 45/100

Intra-articular corticosteroid injections, developed by Pfizer Inc., are used to treat various joint-related conditions. The mechanism involves reducing inflammation within the joint. Key indications include osteoarthritis of the knee and hip, rheumatoid arthritis, tendinitis, and bursitis. This treatment has a significant commercial presence, with $21.2B in revenue. Clinical differentiation lies in its targeted approach to joint inflammation. Commercial significance is evident in its widespread use. Pipeline developments are not specified.

At a glance

Generic nameintra-articular-corticosteroid-injections
SponsorPfizer
Drug classCorticosteroid
TargetGlucocorticoid receptor
Therapeutic areaImmunology
PhaseFDA-approved

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: